A phase I, open-label, vaccination study to evaluate the safety and immunogenicity of the GSK Biologicals recombinant CMV gB sub-unit vaccine GSK1492903A in CMV-seronegative healthy male adult subjects.

Trial Profile

A phase I, open-label, vaccination study to evaluate the safety and immunogenicity of the GSK Biologicals recombinant CMV gB sub-unit vaccine GSK1492903A in CMV-seronegative healthy male adult subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Cytomegalovirus glycoprotein vaccine (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Nov 2011 Actual patient number is 40 according to ClinicalTrials.gov. (Parent trial: NCT00435396).
    • 27 Oct 2008 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 12 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top